Myelodysplastic Syndrome Clinical Trial

Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)

Summary

This is an open-label, two-arm, phase III non-inferiority trial to evaluate the safety of a liberalized hospital diet inclusive of fresh fruits and vegetables to a neutropenic diet in patients with prolonged neutropenia. Both cohorts and diets will adhere to the hygiene and common sense advice listed in the FDA-endorsed food safety guidelines.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age 18 years or older
Undergoing treatment for hematologic malignancies or HSCT as outlined below:
Underlying diagnosis for non-HSCT patients:
Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) receiving induction or reinduction chemotherapy; OR
Acute lymphoblastic leukemia (ALL) receiving an intensive induction chemotherapy (e.g., HyperCVAD±R, CALGB9251, Larsons protocol) with an expected duration of neutropenia of ≥7 days; OR
Allogeneic or autologous HSCT for any indication. For patients undergoing reduced intensity conditioning, only those regimens in which the expected neutropenia is ≥ 7 days are permitted and the patient must reside in the hospital
Expected duration of neutropenia of ≥ 7 days

Exclusion Criteria:

Use of anti infectives for treatment of active systemic infections within 7 days prior to initiation of study diet
Untreated major infection at presentation
Patients with uncontrolled invasive fungal infection (defined as those who have not completed at least 6 weeks of treatment; or who are symptomatic with two CT scans, at least 1 week apart showing uncontrolled disease at the time of initiation of study diet)
Uncontrolled HIV, Hepatitis B and C infection
Receipt of nutrition via enteral tube or total parenteral nutrition at the time of enrollment
Patients unwilling to eat fresh fruit and/or vegetables
Planned management of neutropenia in the outpatient setting

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 3

Estimated Enrollment:

470

Study ID:

NCT03016130

Recruitment Status:

Recruiting

Sponsor:

University of Florida

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

UF Health Cancer Center
Gainesville Florida, 32608, United States More Info
Precious Williams
Contact
352-294-8970
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 3

Estimated Enrollment:

470

Study ID:

NCT03016130

Recruitment Status:

Recruiting

Sponsor:


University of Florida

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.